Trials / Sponsors / Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.
Industry · 10 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related M Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | 2026-03-16 |
| Recruiting | Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related M Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | 2025-02-28 |
| Active Not Recruiting | Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degener Neovascular Age-related Macular Degeneration | Phase 2 | 2022-08-23 |
| Active Not Recruiting | Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) Diabetic Macular Edema, Diabetic Retinopathy | — | 2022-08-10 |
| Active Not Recruiting | Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | — | 2020-12-14 |
| Completed | ADVM-022 Intravitreal Gene Therapy for DME Diabetic Macular Edema, Diabetic Retinopathy | Phase 2 | 2020-05-28 |
| Completed | Long-Term Follow-up Study of ADVM-043 Alpha-1 Antitrypsin Deficiency | — | 2018-12-27 |
| Completed | ADVM-022 Intravitreal Gene Therapy for Wet AMD Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 1 | 2018-11-14 |
| Completed | Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency Alpha 1-Antitrypsin Deficiency | Phase 1 / Phase 2 | 2017-11-28 |
| Completed | A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study) Friedreich's Ataxia | N/A | 2016-07-01 |